DE4026683A1 - Compsn. for treating CNS tumours - contains active cpd. conjugated to saponin, flavone or saccharide, to allow binding to lipid bi-layer of tumour cells - Google Patents
Compsn. for treating CNS tumours - contains active cpd. conjugated to saponin, flavone or saccharide, to allow binding to lipid bi-layer of tumour cellsInfo
- Publication number
- DE4026683A1 DE4026683A1 DE19904026683 DE4026683A DE4026683A1 DE 4026683 A1 DE4026683 A1 DE 4026683A1 DE 19904026683 DE19904026683 DE 19904026683 DE 4026683 A DE4026683 A DE 4026683A DE 4026683 A1 DE4026683 A1 DE 4026683A1
- Authority
- DE
- Germany
- Prior art keywords
- saccharide
- flavone
- saponin
- lipid
- compsn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229930003944 flavone Natural products 0.000 title claims abstract description 5
- 235000011949 flavones Nutrition 0.000 title claims abstract description 5
- 229930182490 saponin Natural products 0.000 title claims abstract description 5
- 150000007949 saponins Chemical class 0.000 title claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 title abstract description 4
- 150000001720 carbohydrates Chemical class 0.000 title description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title description 2
- 150000002212 flavone derivatives Chemical class 0.000 title description 2
- 150000002632 lipids Chemical class 0.000 title description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 title description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title description 2
- 210000004881 tumor cell Anatomy 0.000 title 1
- 239000000126 substance Substances 0.000 claims abstract description 7
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 6
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 235000017709 saponins Nutrition 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 150000002213 flavones Chemical class 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000003211 malignant effect Effects 0.000 claims description 8
- 230000002949 hemolytic effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 8
- 230000004888 barrier function Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 210000000278 spinal cord Anatomy 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 5
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung betrifft Präparat zum Zerspalten von Gewebe der bösartigen Wucherungen durch biochemische Einwirkung auf die Membranen der bösartigen Zellen.The invention relates to preparation for splitting tissue the malignant growths through biochemical action on the membranes of the malignant cells.
Das erwähnte Präparat soll durch die Bindung an die Lipiden- Doppelschicht der Membranen der bösartigen Zellen spezifische Reaktion des humoralen Bestandteiles des Immunsystems und dadurch die Zerspaltung der bösartigen Zellen hervorrufen.The preparation mentioned is said to bind to the lipid Double layer of the membranes of the malignant cells specific Response of the humoral component of the immune system and thereby causing the breakdown of malignant cells.
Die bisherigen Methoden der chemischen Beeinflussung der bösartigen Gewebe sind überwiegend auf der toxischen Einwir kung der Chemotherapeutika gegründet, die das Wuchern der bösartigen Gewebe beeinflussen.The previous methods of influencing the chemical malignant tissues are predominantly on the toxic act Kung the chemotherapeutic drugs founded, which the proliferation of affect malignant tissue.
Diese Präparate beeinflussen jedoch außer den bösartigen Wucherungen auch die physiologisch aktiven Gewebe, z. B. Leber oder Knochenmark, und haben dadurch negative Wirkung auf Blutbildung und Metabolismus. Die Toxizität der meisten bekannten Chemotherapeutika verhindert es, daß notwendige Dosis verabreicht werden kann. Die biochemischen Schutz barrieren verhindern es, daß die Chemotherapeutika in das Zentrale Nervensystem durchdringen und dadurch ist die Behandlung der Tumore im zentralem Nervensystem unmöglich.However, these preparations affect besides the malignant ones Growths also include the physiologically active tissues, e.g. B. liver or bone marrow, and thereby have a negative effect on Blood formation and metabolism. The toxicity of most Known chemotherapy drugs prevent the necessary Dose can be administered. The biochemical protection Barriers prevent the chemotherapy drugs from entering the Penetrate central nervous system and this is the Treatment of tumors in the central nervous system impossible.
Der Erfindung liegt die Aufgabe zugrunde, die negativen Nebenwirkungen zu beseitigen, die die Behandlung des Krebses mit Chemotherapeutika begleiten, und die biochemische Be einflussung der bösartigen Tumoren im zentralen Nervensystem zu ermöglichen.The invention has for its object the negative Eliminate side effects that treat cancer accompany with chemotherapy drugs, and the biochemical Be influence of malignant tumors in the central nervous system to enable.
Diese Aufgabe wird erfindungsgemäßig durch das Präparat zum Zerspalten von Gewebe der bösartigen Wucherungen mittels bio chemischer Einwirkung auf die Membranen der bösartigen Zellen gelöst. This object is achieved by the preparation for Splitting tissue of malignant growths using bio chemical action on the membranes of the malignant cells solved.
Aktiver Bestandteil des Präparates ist organische Substanz, die untoxisch und sterisch entsprechend ist, vom folgenden Charakter:The active ingredient of the preparation is organic substance, which is non-toxic and sterically appropriate, from the following Character:
wobei X organische untoxische Substanz ist, die drei Bindungs positionen hat. Auf der Position R1 ist der biologische Träger gebunden (gewöhnlich Protein oder Sacharid) und die Positionen R2 und R3 sind 6,48 A voneinander entfernt.where X is an organic non-toxic substance that has three binding positions. The biological carrier is bound at position R 1 (usually protein or saccharide) and positions R 2 and R 3 are 6.48 A apart.
Dieser wirksame Hauptbestandteil ist im Präparat durch biolo gische Stabilisatoren des pH-Wertes, durch Substanzen, die os motische Werte beeinflussen und durch kolloidalen Stabilisator ergänzt. Es kann weiter durch Hilfssubstanzen ergänzt werden, die komplexe Wirkung sichern, vor allem durch nichthämolysierende Saponine, Flavone, Sacharide usw.This effective main ingredient is in the preparation by biolo gic stabilizers of the pH, by substances that os affect motive values and by colloidal stabilizer added. It can be supplemented by auxiliary substances, secure the complex effect, especially through non-hemolysing Saponins, flavones, saccharides etc.
Die mit der Erfindung erzielten Vorteile bestehen insbesondere darin, daß statt der chemischen Mittel mit negativen Nebenwirkun gen das Präparat gemäß Erfindung verwendet werden kann, das keine negativen Nebenwirkungen aufweist.The advantages achieved with the invention are in particular in that instead of chemical agents with negative side effects gene the preparation according to the invention can be used that has no negative side effects.
Die Wirkungssubstanzen werden ausschließlich aus Pflanzen gewonnen, sind nicht toxisch, können durch die biochemischen Barrieren in Gehirn und Rückenmark durchdringen. The active substances are made exclusively from plants obtained, are non-toxic, can by biochemical Penetrate barriers in the brain and spinal cord.
Das Präparat gemäß Erfindung kann z. B. folgende Zusammensetzung
(bezogen auf Trockenmasse) haben:
30-32% Aukubin-Formel:The preparation according to the invention can e.g. B. have the following composition (based on dry matter):
30-32% Aukubin formula:
12-15% nichthämolysierende Saponin
21-25% Flavone-Komplex
25-28% kolloidaler Stabilisator
ad 100% Saccharide12-15% non-hemolytic saponin
21-25% flavone complex
25-28% colloidal stabilizer
ad 100% saccharides
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904026683 DE4026683A1 (en) | 1990-08-23 | 1990-08-23 | Compsn. for treating CNS tumours - contains active cpd. conjugated to saponin, flavone or saccharide, to allow binding to lipid bi-layer of tumour cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904026683 DE4026683A1 (en) | 1990-08-23 | 1990-08-23 | Compsn. for treating CNS tumours - contains active cpd. conjugated to saponin, flavone or saccharide, to allow binding to lipid bi-layer of tumour cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE4026683A1 true DE4026683A1 (en) | 1992-02-27 |
Family
ID=6412763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19904026683 Withdrawn DE4026683A1 (en) | 1990-08-23 | 1990-08-23 | Compsn. for treating CNS tumours - contains active cpd. conjugated to saponin, flavone or saccharide, to allow binding to lipid bi-layer of tumour cells |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE4026683A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0761226A1 (en) * | 1995-09-06 | 1997-03-12 | Mitsui Norin Co., Ltd. | Method of potentiating antibiotics with polyphenols |
| EP0819433A3 (en) * | 1996-07-18 | 1999-05-12 | Cancer Institute (Hospital) Chinese Acadamy Of Medical Sciences | Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin |
-
1990
- 1990-08-23 DE DE19904026683 patent/DE4026683A1/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0761226A1 (en) * | 1995-09-06 | 1997-03-12 | Mitsui Norin Co., Ltd. | Method of potentiating antibiotics with polyphenols |
| US5807564A (en) * | 1995-09-06 | 1998-09-15 | Mitsui Norin Co., Ltd. | Method of strengthening antibacterial action of antibiotics |
| EP0819433A3 (en) * | 1996-07-18 | 1999-05-12 | Cancer Institute (Hospital) Chinese Acadamy Of Medical Sciences | Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60013164T2 (en) | AJUGA TURKESTANIKA EXTRACT AND ITS COSMETIC USE | |
| DE10262193B4 (en) | Cosmetic use of an active substance for stimulating type 2 and / or type 3 human beta-defensins, use of such an active substance for the preparation of a pharmaceutical composition containing such an active substance and use of such an active substance in the field of tissue reconstruction | |
| DE102008059523A1 (en) | Cosmetic mixture containing ascorbic acid-2-glucoside and ergothioneine | |
| DE2835292C2 (en) | Process for the production of defibrinized and freeze-dried placental cells | |
| DE4026683A1 (en) | Compsn. for treating CNS tumours - contains active cpd. conjugated to saponin, flavone or saccharide, to allow binding to lipid bi-layer of tumour cells | |
| CH711466B1 (en) | Dermocosmetic composition for topical use with penetration-enhancing properties and process for their preparation. | |
| WO2011127994A1 (en) | Active substance complex and formulation comprising it | |
| DE4315866C1 (en) | Compsns. for photo therapy of skin diseases - contain methoxy-psoralene as photosensitiser, and magnesium salt | |
| DE60024969T2 (en) | 2-METHYL-3-BUTENYL-1-PYROPHOSPHORIC ACIDS AND MEANS FOR THE TREATMENT OF LYMPHOCYTES | |
| DE4030015A1 (en) | AGENTS FOR CONTROLLING AIDS VIRUSES | |
| WO1994007509A1 (en) | Topical treatment agent or medicament containing finely divided transparent zinc oxide | |
| DE4236346A1 (en) | Active ingredient group, process for their preparation and their use | |
| DE202021003192U1 (en) | Means with antineoplastic effects | |
| DE68908119T2 (en) | Drugs for intralescent treatment of flaky cell carcinoma with recombinant human alpha interferon. | |
| EP2155335B1 (en) | Pharmaceutical composition, use of the pharmaceutical composition for treating a brain tumor, production process thereof and a kit of parts comprising the pharmaceutical composition | |
| DE3721038A1 (en) | Composition for the treatment of gastric ulcers and chronic gastritis | |
| Ominyi et al. | Ameliorative effects of aqueous seed-extract of Dacryodes edulis on doxorubicin-induced cardiac tissue damage in albino rats | |
| EP1372786B1 (en) | Cytoprotection by phosphotyrosine | |
| DE102006021198B4 (en) | Dermal use of concentrated aqueous solutions of sodium chloride or other non-toxic inorganic or organic sodium salts as a remedy for the skin disease vitiligo | |
| DE19628514C1 (en) | Synergistic inhibitor of HIV replication | |
| DE69825433T2 (en) | ACTIVE SUBSTANCE FOR INHIBITION OF TUMOROUS PROLIFERATION IN WEAVE FROM THE EKTODERM | |
| EP1610821A2 (en) | Agent for the photodynamic diagnosis and therapy of malignant tumors | |
| EP4637796A1 (en) | Pharmaceutical composition for treating a brain tumor | |
| DE69737143T2 (en) | pigment material | |
| Rásonyi | Mechanistic investigations in ochratoxin A induced nephrotoxicity and their relevance for the sex specific renal tumor induction in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |